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Low-Dose Antithymocyte Globulin Has No
Disadvantages to Standard Higher Dose
in Pediatric Kidney Transplant Recipients:
Report From the Pediatric Nephrology
Research Consortium
Isa F. Ashoor1, Robbie A. Beyl2, Charu Gupta3, Amrish Jain4, Stefan G. Kiessling5,
Asha Moudgil3, Hiren P. Patel6, Joseph Sherbotie7, Donald J. Weaver Jr.8, Rima S. Zahr9 and
Vikas R. Dharnidharka10
1Division of Nephrology, Department of Pediatrics, LSU Health New Orleans, New Orleans, Louisiana, USA; 2Pennington
Biomedical Research Center, Baton Rouge, Louisiana, USA; 3Children’s National Hospital, Washington, DC, USA; 4Department
of Pediatrics, Wayne State University, Detroit, Michigan, USA; 5Department of Pediatrics, University of Kentucky, Lexington,
Kentucky, USA; 6Nationwide Children’s Hospital, Columbus, Ohio, USA; 7Department of Pediatrics, University of Utah School
of Medicine, Salt Lake City, Utah, USA; 8Atrium Health Levine Children’s, Charlotte, North Carolina, USA; 9Department of
Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee, USA; and 10Division of Pediatric Nephrology,
Hypertension and Pheresis, Washington University and St. Louis Children’s Hospital, St. Louis, Missouri, USA
Introduction: Rabbit antithymocyte globulin (rATG) dosing strategies for induction in pediatric kidney
transplantation vary between centers. It is not known whether a lower rATG induction dose provides safe
and effective immunosuppression compared with a “standard” higher dose.
Methods: We performed a retrospective multicenter study of all isolated first-time kidney transplant
recipients <21 years old who received rATG induction between 1 January 2010 and 31 December 2014 at 9
pediatric centers. An a priori cutoff of a 4.5-mg/kg cumulative rATG dose was used to identify low (# 4.5
mg/kg) and standard (> 4.5 mg/kg) exposure groups. Outcomes examined included 12 months post-
transplant graft function (estimated glomerular filtration rate [eGFR]); the occurrence of acute rejection,
donor-specific antibody (DSA), neutropenia, and viral infection (cytomegalovirus [CMV], Epstein-Barr virus
[EBV], and BK virus); and 24-month outcomes of posttransplant lymphoproliferative disorder (PTLD)
occurrence and patient and graft survival.
Results: Two hundred thirty-five patients were included. Baseline features of the low and standard rATG
dose groups were similar. By 12 months, the rATG dose group had no significant impact on the occurrence
of neutropenia, positive DSA, or viral polymerase chain reaction (PCR). Graft function was similar. Acute
rejection rates were similar at 17% (low dose) versus 19% (standard dose) (P ¼ 0.13). By 24 months, graft
survival (96.4% vs. 94.6%) and patient survival (100% vs. 99.3%) were similar between the low- and
standard-dose groups (P ¼ 0.54 and 0.46), whereas the occurrence of PTLD trended higher in the standard-
dose group (0% vs. 2.6%, P ¼ 0.07).
Conclusion: A low rATG induction dose # 4.5 mg/kg provided safe and effective outcomes in this multi-
center low immunologic risk pediatric cohort. Prospective studies are warranted to define the optimal
rATG induction dose in pediatric kidney transplantation.
Kidney Int Rep (2021) 6, 995–1002; https://doi.org/10.1016/j.ekir.2021.01.007
KEYWORDS: induction immunosuppression; kidney transplantation; pediatric; rabbit antithymocyte globulin
ª 2021 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
P
otent immunosuppression in the form of depleting
antibody induction therapy has been credited with
a significant reduction in first-year acute kidney trans-
plant rejection rates compared with nondepleting or no
induction therapy.1,2 The majority of US pediatric kid-
ney transplant programs use induction therapy at the
time of kidney transplantation,3 with rATG being the
most commonly used lymphocyte-depleting induction
agent in the United States.4 Up until 2017, the use of
rATG for that indication was considered off-label
because its original US Food and Drug Administration
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approval was limited to the treatment of established
acute kidney transplant rejection in a wide range of 7
to 14 days at a 1.5-mg/kg/dose.5 As such, a variety of
dosing protocols existed for induction, leading to a
wide range of center-specific cumulative dosing targets
in both pediatric and adult kidney transplant recipi-
ents.4 Given the expense associated with rATG use
and the well-documented enhanced risk for infections,6
there has been a movement toward a limited exposure
approach in dosing and administration.7,8 The current
US Food and Drug Administration dosing guidance rec-
ommends a minimum of 4 doses of rATG at 1.5 mg/kg
for a cumulative dose exposure minimum of 6 mg/kg
for induction purposes,5 whereas prior studies that
established the efficacy of rATG as an induction agent
to prevent acute rejection have used a minimum of 5
doses for a cumulative exposure of 7.5 mg/kg of
body weight.1 In this study, we sought to determine
whether a lower rATG induction dosing regimen is
effective and safe in a multicenter US cohort of pediat-
ric kidney transplant recipients.
METHODS
Study Design
This is a retrospective multicenter study that collected
data from 9 member institutions within the Pediatric
Nephrology Research Consortium (PNRC). The PNRC is
a collaborative group of North American pediatric
nephrology centers that aims to facilitate collaborative
clinical and translational research, define best practices,
and promote career development of their members. The
study was approved by the local institutional review
board of each participating institution with a waiver of
informed consent. All clinical research described in this
article adheres to the Declaration of Helsinki. The
clinical and research activities being reported are
consistent with the Principles of the Declaration of
Istanbul as outlined in the Declaration of Istanbul on
Organ Trafficking and Transplant Tourism.9
The inclusion criteria were as follows: all isolated
first-time pediatric recipients <21 years old at the time
of kidney transplant who received rATG induction
between 1 January 2010, and 31 December 2014. Re-
cipients of repeat kidney transplants or multiorgan
transplants and recipients who received induction
other than rATG or no induction therapy were
excluded from the study.
Exposure Variable
Based on a single rATG dose of 1.5 mg/kg of body
weight, the rATG cumulative exposure threshold was
set a priori at 3 doses or less (# 4.5 mg/kg) for the low-
dose exposure group and at greater than 3 doses (> 4.5
mg/kg) for the standard-dose exposure group. Each
center followed its individual center-specific immuno-
suppression protocol and rATG induction dosing
strategy at the discretion of the treating physician. The
assignment of subjects to the low-dose and standard-
dose exposure groups was based on the actual deliv-
ered rATG dose at the time of induction.
Outcomes
We compared 12-month outcome measures of graft
function (eGFR), acute rejection, DSA development,
neutropenia, and the occurrence of viral infection
(CMV, EBV, and BK virus), as well as 24-month
outcome measures of PTLD occurrence and patient
and graft survival.
Data Collection
Baseline demographic and clinical data were collected
at the time of admission and discharge from index
kidney transplant hospitalization and subsequently at
6, 12, and 24 months after kidney transplantation.
eGFR was calculated using the modified Schwartz for-
mula.10 Acute rejection episodes captured all biopsy-
proven acute rejection events, including borderline
cellular rejection, acute cellular rejection, and
antibody-mediated rejection. Neutropenia was defined
as an absolute neutrophil count < 1500/mm3. Viral
infections included both symptomatic infections and
asymptomatic viremia on surveillance monitoring as
measured by PCR testing at each individual center.
Additional information regarding participating centers’
practice patterns with regard to surveillance biopsy,
DSA, and viral testing as well as immunosuppression
drug level targets is summarized in Supplementary
Table S1.
Statistical Analysis
Continuous variables were summarized as means with
SD and medians with interquartile ranges. The cumu-
lative rATG induction dose was summarized numeri-
cally by exposure group; t-tests based on linear models
were used to test for group differences for continuous
outcomes. Categoric variables were summarized as
frequencies, and tests of association between them were
conducted using chi-square tests. Graft survival was
calculated using Kaplan-Meier estimates. A generalized
logistic regression model was used to test the odds of an
event occurring over time including patient survival,
acute rejection, occurrence of DSA, neutropenia, or
positive viral PCR testing. Potential covariates consid-
ered for the model included baseline characteristics
(age, sex, race, end-stage kidney disease etiology,
transplant type, panel-reactive antibody, and CMV and
EBV risk category), center effect, and immunosup-
pression at discharge. Sensitivity analysis at the 5.0-
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mg/kg, 5.5-mg/kg, and 6.0-mg/kg rATG cumulative
dose thresholds was completed for the outcomes of
acute rejection, neutropenia occurrence, and graft
survival.
RESULTS
rATGDosing Trends and Baseline Characteristics
of Low-dose and Standard-dose rATG Exposure
Groups
Two-hundred eighty-two kidney transplant re-
cipients were included from 9 member centers of
the PNRC. Complete data on rATG dosing were
available for 235 recipients who were included in
the final analysis (Supplementary Table S2). Using
an a priori cutoff of 3 doses of rATG induction at
1.5 mg/kg per dose, we defined the low-dose
exposure group (# 4.5-mg/kg cumulative rATG
induction dose), which included 83 recipients with
a median cumulative exposure dose of 4.11 mg/kg,
and the standard dose exposure group (> 4.5-mg/
kg cumulative rATG induction dose), which
included 152 recipients with a median cumulative
exposure dose of 5.96 mg/kg. Baseline characteris-
tics including age, sex, race, etiology of end-stage
kidney disease, transplant type, panel-reactive
antibody, and CMV/EBV risk status category at
the time of transplant admission were similar be-
tween both groups (Table 1). Overall, recipients
were predominantly white, male, nonsensitized
deceased donor recipients with intermediate risk for
both CMV and EBV reactivation. At the time of
hospital discharge from index kidney transplant
admission (Table 2), recipients in both rATG dose
exposure groups had similar graft function (creati-
nine-based modified Schwartz mean eGFR of 79 ml/
min/1.73 m2 in the low-dose exposure group vs. 75
ml/min/1.73 m2 in the standard-dose exposure
group) and similar rates of antiviral prophylaxis
(98.8% in the low-dose group vs. 98% in the
standard-dose group). Approximately 64% of the
study cohort received a steroid avoidance or wean
protocol in which steroids were discontinued
within 3 to 14 days after kidney transplant. Both
groups were similar in terms of tacrolimus adoption
as a long-term immunosuppressant agent at the time
of discharge (98.8% vs. 96.7%); however, the low-
dose group recipients were less likely to be on
mycophenolate (92.8% vs. 98%, P ¼ 0.05) and
prednisone (25.3% vs. 41.4%, P ¼ 0.01). Because
no significant differences were noted in baseline
characteristics between rATG dose groups, the final
logistic regression model used for the following
analyses only included rATG dose, center effects,
and whether the subject received prednisone ther-
apy at discharge from kidney transplant admission
as covariates. The limited availability of subjects
not receiving mycophenolate mofetil at the time of
discharge from kidney transplant admission pre-
cluded this variable from being used in the final
model.
Table 1. Baseline characteristics at the time of transplant admission
Low-dose rATG
induction £ 4.5 mg/kg
(n [ 83)
Standard-dose rATG




Age (mean), yr 13 12.1 0.2




















PRA (mean  standard
error), %
Class I 4.5  1.6 2.3  1 0.26
% Subjects with class I
PRA > 80%
0 0
Class II 5.9  1.7 2.1  1.1 0.07
% Subjects with class II
PRA > 80%
0 0








CMV, cytomegalovirus; EBV, Epstein-Barr virus; ESKD, end-stage kidney disease; PRA,
panel reactive antibody; rATG, rabbit antithymocyte globulin.
Table 2. Baseline characteristics at the time of discharge from
index kidney transplant admission
Low-dose rATG
induction £ 4.5 mg/kg
(n [ 83)
Standard-dose rATG









Tacrolimus 98.8 96.7 0.33
Mycophenolate 92.8 98 0.05
Prednisone 25.3 41.4 0.01
Other 4 3 0.9
Antiviral prophylaxis (yes),% 98.8 98 0.66
eGFR, estimate glomerular filtration rate; rAGT, rabbit antithymocyte globulin.
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The Effect of rATG Exposure Group on Patient
and Graft Outcomes Through 12 Months of
Follow-up
Graft function at 12 months posttransplant as measured
by eGFR was similar in both groups at a mean eGFR of
70 ml/min/1.73 m2 in the low-dose exposure group
versus 72 ml/min/1.73 m2 in the standard-dose expo-
sure group (P ¼ 0.6, Figure 1). Acute rejection rates
and DSA development rates were similar in both
groups (Figure 2a and b). Seventeen percent of re-
cipients in the low-dose exposure group experienced
an acute rejection episode in the first year post-
transplantation with 71% of these episodes occurring
in the first 6 months posttransplant, whereas 19%
experienced an acute rejection episode in the first year
posttransplantation in the standard-dose group with
41% occurring in the first 6 months posttransplantation.
In the low rATG dose exposure group, data on rejection
histology were available for 93% of all cases. Of those,
21% had borderline cell-mediated rejection, 43% had
acute cell-mediated rejection (Banff IA or greater
severity), 14% had antibody-mediated rejection, and
22% had mixed acute cellular and antibody-mediated
rejection. In the standard rATG dose exposure group,
data on rejection histology were available for 97% of all
cases. Of those, 16% had borderline cell-mediated
rejection, 55% had acute cell-mediated rejection (Banff
IA or greater severity), 6% had antibody-mediated
rejection, and 23% had mixed acute cellular and
antibody-mediated rejection. Ninety percent of low-dose
rATG induction subjects with early rejection in the first
6 months after kidney transplant were maintained on
steroid-free regimens as opposed to 47% of the
standard-dose rATG induction subjects experiencing an
acute rejection in the same time frame.
With regard to DSA development, 22.8% and 24.4%
developed a de novo DSA over the first year in the low-
dose and standard-dose groups, respectively, with
most DSAs developing between 6 to 12 months
posttransplantation at 68% and 60% for the low-dose
and standard-dose groups. DSA class was not speci-
fied in 33% of the low rATG dose group and 13% of
the standard rATG dose group. In subjects with com-
plete data on DSA specificity, class I DSAs accounted
for only 5% of all positive DSAs in the standard rATG
dose group with the remainder having either class II
(60%) or combined class I and II DSAs (35%). Subjects
in the low rATG dose group had either class II (67%) or
combined class I and II DSAs (33%).
The rates of neutropenia were similar between both
groups as well, with the majority of patients developing
neutropenia in the first 6 months after kidney trans-
plantation (Figure 3a). Approximately 43.5% of re-
cipients in the low-dose group developed neutropenia in
the first 6 months compared with 48.6% in the
standard-dose group. The percentage of recipients with
neutropenia dropped to 19% between 6 and 12 months
posttransplant in the low-dose group and to 16% in the
standard-dose group. In the low-dose exposure group,
24% of neutropenic subjects experienced severe neu-
tropenia with an absolute neutrophil count < 500/mm3
as opposed to 27% of neutropenic subjects in the
standard-dose exposure group. Twenty-four percent of
neutropenia episodes in the low-dose group were asso-
ciated with a serious infection requiring hospitalization,
and 15% received treatment with granulocyte colony-
stimulating factor. This compares to 17% with serious
infections and 5% who received treatment with gran-
ulocyte colony-stimulating factor in the standard-dose
group. Serious infections were similar in both groups
and included viral infections (CMV disease, adenovirus
infection, and EBV disease), bacterial pneumonia, and
urinary tract infections with and without sepsis. The
rate of positive viral PCRs for CMV, EBV, or BK virus
infections was similar in both groups (Figure 3b).
The Effect of rATG Exposure Group on Patient
and Graft Outcomes Through 24 Months of
Follow-up
Graft survival was similar between both groups
through 24 months of follow-up after kidney trans-
plantation (Figure 4). In the low-dose rATG exposure
group, graft survival measured at 100%, 98.8%, and
96.4% through 6, 12, and 24 months of follow-up,
respectively, whereas graft survival in the standard-
dose rATG exposure group measured at 98.7%,
96.7%, and 94.6% at the same time points (P ¼ 0.54).
There were no deaths or PTLD cases reported in the
low-dose group, whereas 1 patient died secondary to
urosepsis (P ¼ 0.46) and 4 patients developed PTLD
(P ¼ 0.07) in the standard-dose group. Three patients
who developed PTLD were diagnosed between 6 and
12 months posttransplantation, whereas the fourth
Figure 1. Graft function comparison between low-dose rabbit
antithymocyte globulin and standard-dose rabbit antithymocyte
globulin exposure groups at 12 months after kidney transplant. eGFR,
estimated glomerular filtration rate.
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patient was diagnosed between 12 and 24 months.
Three of these PTLD patients were in the high-risk EBV
mismatch category (EBV-negative recipients with an
EBV-positive donor), and 1 was of intermediate risk
(both recipient and donor were EBV positive). All pa-
tients were alive and in remission at 24 months post-
transplantation with functioning grafts. Treatment
involved immunosuppression reduction in all patients,
rituximab in 2 patients, and chemotherapy in 1 patient.
Finally, to address the issue of unequal group sizes
and improve the balance of participants within each
group, a sensitivity analysis for the outcomes of acute
rejection, neutropenia occurrence, and graft survival
was performed. Using the rATG cumulative dose cutoffs
of 5.0 mg/kg (n ¼ 118 vs. 117), 5.5 mg/kg (n ¼ 137 vs.
98), and 6.0 mg/kg (n ¼ 162 vs. 73) produced similar
results as 4.5 mg/kg (n ¼ 83 vs. 152), all showing no
significant differences between dosage and outcome.
DISCUSSION
This is the largest and first multicenter cohort study to
examine the relationship between rATG induction dose
exposure and a wide variety of safety and efficacy
outcomes in first-time pediatric kidney transplant re-
cipients. rATG use has increased over time, and it is
currently the most commonly used induction therapy
for kidney transplantation.3,4 However, the lack of
specific dosing recommendations until very recently
has led to many immunosuppressive protocols in the
adult transplant literature, with an overall trend to-
ward a lower cumulative exposure in the most recent
era.7,11–13 We have previously demonstrated a down
trend in median cumulative rATG induction dose from
7.9 mg/kg (1998–2008) to 6.3 mg/kg (2009–2016) in the
North American Pediatric Renal Trials and Collabora-
tive Studies registry.14 In that analysis, we did not
identify a difference in patient and graft outcomes
using a threshold of 5 rATG induction doses (7.5 mg/
kg). Although data from Tsapepas et al.15 have
demonstrated a significantly higher incidence of acute
rejection in adults receiving a 5- to 6-mg/kg cumulative
rATG induction dose compared with those receiving 6
mg/kg or more (essentially a 4-dose threshold), several
other studies demonstrated satisfactory outcomes with
even smaller cumulative rATG induction doses.7,12,13
Because the majority of pediatric recipients are low
immunologic risk, first-time kidney transplant re-
cipients in whom rATG induction is primarily used to
allow the adoption of a steroid avoidance immuno-
suppression protocol, we were most interested in
examining the lower end of the rATG cumulative dose
Figure 2. (a) Acute rejection comparison between low-dose rabbit antithymocyte globulin (rATG) and standard-dose rATG exposure groups at
12 months after kidney transplant. (b) The development of de novo donor-specific antibody comparison between low-dose rATG and standard-
dose rATG exposure groups at 12 months after kidney transplant.
Figure 3. (a) Neutropenia occurrence comparison between low-dose rabbit antithymocyte globulin (rATG) and standard-dose rATG exposure
groups at 12 months after kidney transplant. (b) The occurrence of positive viral polymerase chain reaction testing for either cytomegalovirus
(CMV), Epstein-Barr virus (EBV), or BK virus (BKV) infection comparison between low-dose rATG and standard-dose rATG exposure groups at
12 months after kidney transplant. ANC, absolute neutrophil count.
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spectrum (3 doses or less) compared with higher doses
to identify the lowest safe and effective rATG dose
threshold. By leveraging the collaborative nature of the
PNRC, we were able to recruit a large cohort of pedi-
atric kidney transplant recipients with granular rATG
dosing information and detailed outcome variables
including DSA development and viral infection PCR
positivity that are not typically captured in large na-
tional registries such as the North American Pediatric
Renal Trials and Collaborative Studies registry and the
Scientific Registry of Transplant Recipients database.
Our findings mirror the recent trend toward lower
rATG dosing induction strategies.7,12,13,16 Approxi-
mately one-third of recipients in our cohort received #
4.5 mg/kg in a cumulative rATG induction dose, which
falls below the recent US Food and Drug Administration
label recommendation of 4 doses at 1.5 mg/kg per dose
or a cumulative exposure target of 6 mg/kg. The
“standard” dosing group in our cohort fell more in line
with the recent US Food and Drug Administration label
recommendation with a median cumulative exposure of
5.96 mg/kg, which is generally equivalent to 4 daily
doses at 1.5 mg/kg each and represents a lower exposure
relative to the original clinical trials that popularized
rATG use for induction immunosuppression in kidney
transplantation using a 5-day treatment course.1,11,17
One concern related to lower rATG dose exposure is
decreased efficacy leading to possible increased risk of
acute rejection and how that may impact both graft
function and graft survival. Our findings suggest that
low-dose rATG induction is comparable with standard-
dose rATG induction from short-term acute rejection
prophylaxis, graft function, and graft survival stand-
points. Our acute rejection rate in the first 12 months
posttransplant was similar in both the low and stan-
dard rATG dose groups at 17% and 19%, respectively,
although there was a trend for a higher proportion of
acute rejections in the low-dose group occurring in the
first 6 months posttransplantation. Graft function at 12
months was satisfactory in both groups, with eGFR at
70 and 72 ml/min/1.73 m2. Graft survival was similar as
well through 24 months of follow-up at 96.4% and
94.6% for the low- and standard-dose groups, respec-
tively. Although our study design did not allow for a
3-year longitudinal follow-up, our 2-year graft survival
data fall between 1- and 3-year graft survival data re-
ported in the most recent North American Pediatric
Renal Trials and Collaborative Studies cohort.2 In the
absence of overt clinical rejection or graft failure, we
were interested in assessing the risk of DSA develop-
ment in relation to a lower rATG induction dose, which
may lead to subclinical rejection and subsequent late
acute antibody-mediated rejection not captured in our
follow-up period. Our findings suggest no significant
difference in de novo DSA development through 12
months of follow-up after kidney transplantation based
on the rATG induction dose. The proportion of re-
cipients who developed a de novo DSA (either class I or
class II) in our cohort was 22.8% and 24.4% in the low
and standard rATG dose groups, which is in line with
reported rates in other pediatric studies.18,19 Overall,
those findings are consistent with what has been
shown in smaller single-center, adult studies in which
low rATG dosing protocols demonstrated excellent 1-
year graft outcomes without a significant increase in
acute rejection rates. For example, in comparison with
conventional rATG exposure targets of 6 to 10 mg/kg,
Singh et al.7 reviewed their outcomes using a tailored
rATG cumulative exposure target of 3 to 6 mg/kg over
a 5-year period and found comparable outcomes with
those reported in the annual Scientific Registry of
Transplant Recipients reports.7 Another study by
Grafals et al.13 using a much lower rATG cumulative
exposure target of either 2.25 mg/kg or 3.75 mg/kg
demonstrated a biopsy-proven acute rejection rate of
10% and 17%, respectively, at 1 year follow-up and
similar T-cell subpopulation depletion and repopula-
tion kinetics in both groups.
Posttransplant infections are the leading cause of
death in pediatric kidney transplant recipients and
have surpassed acute rejection as a cause for hospital-
ization.2 Therefore, a major driver for induction
immunosuppression protocols using low-dose rATG is
the concern for a higher risk of opportunistic infections
that may be observed with higher rATG dose expo-
sure.6,8 Paradoxically, a low-dose rATG induction
protocol that inadvertently leads to increased incidence
of early acute rejection requiring further intensification
of immunosuppression can further compound that in-
fectious risk and negate any protective benefit derived
from the low-dose protocol. Similarly, posttransplant
neutropenia, which is observed more frequently in
Figure 4. Graft survival comparison between low-dose rabbit
antithymocyte globulin (rATG) and standard-dose rATG exposure
groups through 24 months after kidney transplant.
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association with rATG induction, can have detrimental
patient and graft outcomes should it lead to serious life-
threatening infections or graft rejection resulting from
mitigation efforts that lower maintenance immuno-
suppression.20 The frequency of posttransplant neu-
tropenia in our cohort was high but no different in
relation to rATG exposure dose. Most of the cases
occurred in the first 6 months posttransplant, with
43.5% and 48.6% of recipients in the low-dose and
standard-dose group developing neutropenia in that
time frame. Similarly, we found no difference in the
occurrence of viral reactivation for CMV, EBV, or BK
virus infection in relation to rATG dose exposure.
Although it is reassuring that there was no significant
difference in patient survival or the occurrence of
PTLD between groups, it is worth noting that the only
death, which was secondary to an infection, and all 4
PTLD cases noted in our cohort belonged to the stan-
dard rATG dose exposure group. In a large analysis
involving 25,127 recipients in the United States Renal
Data System database specifically designed to address
PTLD occurrence in relation to immunosuppression,
the authors found an increased PTLD risk in relation to
a composite of all formulations of antithymocyte
globulin used for induction in patients transplanted
between 1996 and 2000. However, the use of the rATG
formulation (also known as Thymoglobulin), which
was used for induction therapy during our study time
frame, was not specifically linked to an increased risk
in that report.21 In another pediatric-focused analysis,
the increased risk only applied to the equine formula-
tion of antithymocyte globulin.22 Additionally, the
cumulative dose of rATG was not associated with the
development of PTLD in a systematic review of 2246
kidney and heart transplant recipients who received
rATG induction, further suggesting that the antithy-
mocyte globulin formulation and other recipient- and
transplant-related factors may be more relevant to the
development of PTLD.23
Our study has several limitations; as with any other
chart review retrospective analysis, data completeness is
a major limiting factor. In our study, 47 patients of the
enrolled 282 (17%) had received rATG induction but
lacked dosing information to facilitate their classification
to either the low-dose or standard-dose rATG group and
as such were excluded from further analysis. Data
regarding dialysis vintage was lacking, which limited
our ability to control for that variable as a confounding
factor. Although the graft failure rate was small in our
study, causes of graft failure were not collected, limiting
our ability to extrapolate whether graft failures could be
attributed to rATG-relevant adverse events such as
rejection or infection. Data regarding long-term main-
tenance immunosuppression details were limited to
discharge medication records from the index transplant
admission, thus limiting the ability to adjust for changes
in maintenance immunosuppression in our model. Thus,
our study design was specifically limited to capturing
primarily 12-month and a smaller subset of 24-month
outcomes because longer-term outcomes are more
likely to be influenced by multiple unmeasured con-
founding factors such as long-term changes in immu-
nosuppression, whereas the shorter-term outcomes
would more reliably reflect the induction dosing effect.
Another limitation relates to each center using its own
center-specific surveillance biopsy, DSA, and viral
monitoring protocols, which may have affected the
frequency at which borderline rejections, positive DSAs,
or viral PCRs were detected depending on the testing
frequency and positive cutoff thresholds. We attempted
to account for that by adjusting for center effect in our
regression model. The retrospective study design also
limits our ability to draw a causal relationship between
the rATG dose and the outcomes examined; however,
the data are compelling and lay the groundwork for
future prospective cohort analysis and randomized
clinical trials addressing the same question. Also, despite
the large number of patients for a pediatric-focused
study, our study was not sufficiently powered to
examine all the outcome measures described, and our
findings should be viewed as an exploratory analysis
laying the groundwork for future studies. In addition,
although the PNRC offers a platform to conduct large-
scale collaborative research across its member in-
stitutions, we were limited to data from 9 participating
member sites, which can limit the generalizability of our
findings to the larger pediatric transplant community.
However, our findings complement the growing body of
literature available from larger adult-focused or
database-only studies with a wide range of outcomes
linked to granular dosing information and exclusively
focused on a pediatric population.
In conclusion, we have demonstrated that a low
rATG cumulative induction dose# 4.5 mg/kg provides
safe and effective short-term patient and graft out-
comes in this multicenter, low immunologic risk, pe-
diatric kidney transplant cohort. Prospective
longitudinal cohort or randomized controlled trial
studies are warranted to define the optimal rATG
dosing strategy in pediatric kidney transplantation.
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